Prices delayed ≤15 min
AI Analysis Summary
Bristol-Myers Squibb Company Explained: Products, Market Position & Moat Bristol-Myers Squibb Company (BMY) is a prominent player in the healthcare sector, specifically within the drug manufacturing industry. Headquartered in Princeton, NJ, the company focuses on discovering, developing, licensing, manufacturing, and marketing biopharmaceutical products across various therapeutic areas, including oncology, hematology, cardiovascular, and immunology. Key products include Revlimid, an oral immunomodulatory drug for multiple myeloma, and Opdivo, which is used for various cancer treatments. The company has established a competitive edge through its strong pipeline of innovative therapies and a diverse portfolio that addresses critical health needs. Despite the competitive landscape, BMY maintains a solid market position, benefiting from its reputation for quality and effectiveness, which enhances its economic moat. This unique positioning allows the company to navigate challenges in the pharmaceutical industry, such as patent expirations and increasing competition. BMY By the Numbers: Revenue, Margins & Profitability In the latest fiscal year, Bristol-Myers Squibb reported revenue of $48.19 billion, a slight decline from $48.30 billion in the previous year, marking a year-over-year decrease of 0.2%. Over the past three years, the revenue trajectory has shown some fluctuations, with figures moving from $45.01 billion in 2023 to $48.30 billion in 2024 and then slightly retracting in 2025. The company's gross profit stands at $34.26 billion, reflecting a robust gross margin of 71.1%. Net income for the latest year reached $7.05 billion, translating to a net margin of 14.6%, which highlights effective cost management amidst a challenging revenue environment. Earnings per share (EPS) are reported at $3.46, showcasing a significant growth of 178.5% compared to the prior year. These figures underscore Bristol-Myers Squibb's ability to maintain profitability even as revenue experiences minor fluctuations. Debt, Liquidity & Balance Sheet Resilience at BMY Bristol-Myers Squibb's financial health is characterized by a total debt of $44.83 billion against total assets of $90.04 billion, resulting in a debt-to-equity ratio of 2.43. This level of debt suggests a highly leveraged position, which could pose risks if not managed effectively. The company holds cash reserves of $10.21 billion, providing a buffer against its debt obligations and facilitating operational flexibility. With a current ratio of 1.26, BMY demonstrates adequate liquidity to cover short-term liabilities, although the ratio is on the lower end of the spectrum for the industry. The net debt position stands at $34.62 billion, indicating that while the company is heavily indebted, it possesses sufficient cash to manage its obligations. Overall, the balance sheet reflects a mix of resilience and risk, necessitating careful monitoring of debt levels. Cash Generation & Capital Allocation Strategy at Bristol-Myers Squibb Company Bristol-Myers Squibb reported operating cash flow of $14.16 billion, evidencing the company's strong ability to generate cash from its core operations. The free cash flow stands at $12.85 billion, although it has experienced a decline of 7.9% year-over-year, which may raise concerns regarding future cash generation capabilities. The company has allocated capital primarily towards dividends, having paid out $5.04 billion, indicating a commitment to returning value to shareholders. However, there have been no stock buybacks reported, suggesting a cautious approach to capital allocation amidst ongoing competitive pressures. As BMY continues to navigate its operational landscape, maintaining healthy cash flow will be crucial for funding research and development initiatives, as well as managing its debt obligations. Decoding BMY's Valuation Multiples Bristol-Myers Squibb currently trades at a price-to-earnings (P/E) ratio of 18.17, which is relatively modest compared to the broader healthcare sector. The price-to-book ratio stands at 6.95, while the price-to-sales ratio is 2.66. These valuation multiples suggest that the stock may be fairly valued in relation to its earnings and book value, reflecting moderate growth expectations from investors. The absence of a forward P/E ratio suggests that analysts may be cautious about projecting future earnings due to uncertainties in the market. With these metrics in mind, BMY's current valuation indicates that investors are looking for stable earnings rather than explosive growth, which could be appealing for those seeking a balance between risk and reward. BMY Growth Trajectory: Estimates, Catalysts & Analyst Sentiment While specific forward estimates and analyst sentiment are currently unavailable, the growth trajectory for Bristol-Myers Squibb hinges on several key catalysts, including the continued performance of existing products and the successful launch of new therapies. The company's robust pipeline and ongoing research efforts position it well for potential market expansion opportunities in the coming years. BMY's focus on innovative treatments, particularly in oncology and immunology, could drive future revenue growth, especially as global healthcare needs evolve. Investors should monitor any updates on clinical trials and product launches, as these developments will be critical in shaping market perceptions and potential earnings surprises moving forward. Key Risks Every BMY Investor Should Weigh Investing in Bristol-Myers Squibb carries inherent risks that potential investors should carefully consider. The company's debt burden of $44.83 billion may pose challenges, particularly in a rising interest rate environment which could increase borrowing costs. Margin compression is another concern, as competitive pricing and regulatory pressures could impact profitability. Further, BMY faces competitive threats from both established players and new entrants within the drug manufacturing sector, which could affect market share. Additionally, regulatory risks related to drug approvals and compliance are significant, as any delays or rejections can materially impact revenue. With a beta of 0.26, the stock exhibits lower volatility compared to the market, providing a buffer against broader economic fluctuations, yet it remains sensitive to sector-specific developments. Bristol-Myers Squibb Company's 2026 Investment Case, Summarized In summary, Bristol-Myers Squibb presents a complex investment case as it navigates a challenging market landscape. The company’s strong revenue generation and profitability metrics are tempered by high leverage and potential risks related to competitive pressures and regulatory environments. While it may not appeal to income-focused investors due to the absence of a dividend yield, growth-oriented investors might find value in its innovative pipeline and established market presence. Those considering BMY should remain vigilant about upcoming clinical trial results, product launches, and overall market dynamics. As the healthcare sector continues to evolve, Bristol-Myers Squibb's ability to adapt and innovate will be critical to its long-term success and attractiveness as an investment.
Financial figures come from Bristol-Myers Squibb Company's latest annual SEC filing (fiscal year 2025), so they can lag recent quarters. Prices are delayed up to 15 minutes.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectab
Frequently Asked Questions about BMY
What does Bristol-Myers Squibb Company (BMY) do?
Bristol-Myers Squibb Company specializes in the discovery, development, licensing, manufacturing, and marketing of biopharmaceutical products across the globe. Their portfolio includes treatments for various diseases such as cancer, cardiovascular conditions, and COVID-19, with notable products like Revlimid, which is used in hematology.
Is BMY stock a good investment in 2026?
Looking ahead to 2026, BMY's current P/E ratio of 18.17 suggests it may be fairly valued compared to its peers in the healthcare sector. However, with a slight revenue decline of 0.2%, investors should weigh potential growth against its established profitability metrics, including a solid net income of $7.05 billion.
What is Bristol-Myers Squibb Company's market capitalisation and stock price?
Currently, Bristol-Myers Squibb's stock is priced at $62.86, contributing to a market capitalization of approximately $128.41 billion. Over the past year, the stock has fluctuated between a high of $68.64 and a low of $42.52, reflecting some volatility.
Does BMY pay dividends to shareholders?
Bristol-Myers Squibb does not distribute dividends to its shareholders at this time. Instead, the company appears to be focusing on reinvesting its profits into growth initiatives, as indicated by its substantial free cash flow of $12.85 billion.
How profitable is Bristol-Myers Squibb Company?
Bristol-Myers Squibb boasts a net income of $7.05 billion, which translates to a net margin of 14.6%. Additionally, the company shows a strong return on equity (ROE) of 38.2%, highlighting its effective management of shareholder equity and solid free cash flow.
What is BMY's P/E ratio and is the stock overvalued?
With a P/E ratio of 18.17, BMY's valuation is relatively moderate when compared to the broader drug manufacturing industry. Investors may find this appealing, but they should consider the stagnant revenue growth as a potential indicator of future performance.
How much debt does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb has a debt-to-equity ratio of 2.43, which indicates a significant reliance on debt financing. However, the company maintains a current ratio of 1.26, suggesting it has enough short-term assets to cover its liabilities.
What is BMY's 52-week trading range?
The 52-week trading range for BMY is between $42.52 and $68.64, showcasing a considerable price variation. At its current price of $62.86, it sits closer to the upper end of this range, indicating a relatively strong market position.
Is BMY a growth stock or value stock?
BMY appears to lean more towards being a value stock, particularly given its P/E ratio and its recent revenue decline of 0.2%. While it has a respectable EPS of $3.46, the lack of significant revenue growth may not align with typical growth stock characteristics.
What are the main risks of investing in BMY?
Investing in BMY carries specific risks, including its high debt-to-equity ratio of 2.43, which could impact financial stability. Additionally, with a beta of 0.26, the stock is less volatile than the market, but competition in the healthcare sector remains a constant threat.